Dr Andreas Vogel | Head of European Regulatory
Bluebird Bio

Dr Andreas Vogel, Head of European Regulatory, Bluebird Bio

Andreas Vogel, Ph.D., is Senior Director, Regulatory Science at bluebird bio, a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies. A developmental biologist by training, he joined the pharmaceutical and biotech industries in 2001 as a researcher at Exelixis (Germany) before changing to Regulatory Science in 2004. He has held positions at F. Hoffmann-La Roche, Voisin Consulting Life Sciences and Laboratoires CTRS. At bluebird bio, Andreas has been heading the European Regulatory team since 2017.

Appearances:



Day 2, Nov 8 @ 09:25

Speaking from experience, expedited regulatory pathways in gaining EMA PRIME examples – Where do we go from there?

  • Paving the way for biotechs to gain approval and access
  • Recent changes and future amendments to regulatory issues surrounding orphan drugs approval
  • How are companies interacting the payers and how to close the gap to allow treatments to reach patients
Discussion with payer and PRIME designated companies
last published: 17/Oct/18 12:05 GMT

back to speakers

Follow us on

 

Sign Up for Event Updates

Get Involved At World Orphan Drug Congress 2018

 

To Sponsor Or Exhibit

 

Andrew Mears
andrew.mears@terrapinn.com
t/ +44 20 7092 1228

 

To Speak

 

Wing-Yun Cheung
wing-yun.cheung@terrapinn.com
t/ +44 20 7092 1172

 

To Register

 

Issa Mauthoor
issa.mauthoor@terrapinn.com
t/ +44 20 7092 1257